Search the source libraries

The impacts associated with having ADHD: an umbrella review.

Introduction: Attention Deficit Hyperactivity Disorder (ADHD) affects up to 5% of the population and is characterised by symptoms of impulsivity, hyperactivity and inattention. These symptoms are significantly impairing and carry additional risks for children and adults with ADHD, including negative mental health (e.g. depression), physical health (e.g. obesity) and societal outcomes (e.g. imprisonment, divorce). Very few studies have attempted to synthesise these risks in one publication due to the breadth of evidence published on the adverse outcomes of ADHD. Methods: An umbrella review was performed to identify reviews (systematic, meta-analysis and narrative) that investigate the risks arising from having ADHD. We conducted a narrative synthesis of the findings and conducted a quality review of the included publications. Results: Upon searching five databases, 16,675 records were identified. Of these, 125 reviews met the criteria for inclusion. A narrative synthesis of these findings highlighted three key domains of risks associated with ADHD: mental health, physical health, social and lifestyle. Most reviews were of good and moderate quality. Discussion: This review highlights the many risks associated with having ADHD, beyond its three key symptom domains and the impact of the condition on daily functioning. Registration: International Prospective Register of Systematic Reviews (PROSPERO CRD42023404073).

Frontiers in psychiatry · review · 54 citationsread the source →

A task-shared, collaborative care psychosocial intervention for improving depressive symptomatology among older adults in a socioeconomically deprived area of Brazil (PROACTIVE): a pragmatic, two-arm, parallel-group, cluster-randomised controlled trial.

Background: There is an urgent need to reduce the burden of depression among older adults in low-income and middle-income countries (LMICs). We aimed to evaluate the efficacy of a task-shared, collaborative care psychosocial intervention for improving recovery from depression in older adults in Brazil. Methods: PROACTIVE was a pragmatic, two-arm, parallel-group, cluster-randomised controlled trial conducted in Guarulhos, Brazil. Primary care clinics (clusters) were stratified by educational level and randomly allocated (1:1) to either enhanced usual care alone (control group) or to enhanced usual care plus the psychosocial intervention (intervention group), which involved a 17-week psychosocial programme based on psychoeducation and behavioural activation approaches. Individuals approached for the initial screening assessment were selected randomly from a list of individuals provided by the Health Secretariat of Guarulhos. Face-to-face baseline assessments were conducted among adults aged 60 years or older registered with one of the primary care clinics and identified with clinically significant depressive symptomatology (9-item Patient Health Questionnaire [PHQ-9] score ≥10). Community health workers delivered the programme through home sessions, supported by a dedicated tablet application. Masking of clinic staff and community health workers who delivered the intervention was not feasible; however, research assistants conducting recruitment and follow-up assessments were masked to trial allocation. The primary outcome was recovery from depression (PHQ-9 score <10) at 8-month follow-up. All primary analyses were performed by intention to treat with imputed data. Adaptations to the protocol were made due to the COVID-19 pandemic; recruitment and intervention home sessions were stopped, and follow-up assessments were conducted by telephone. This trial is registered with the ISRCTN registry, ISRCTN57805470. Findings: We identified 24 primary care clinics in Guarulhos that were willing to participate, of which 20 were randomly allocated to either the control group (ten [50%] clusters) or to the intervention group (ten [50%] clusters). The four remaining eligible clusters were kept as reserves. Between May 23, 2019, and Feb 21, 2020, 8146 individuals were assessed for eligibility, of whom 715 (8·8%) participants were recruited: 355 (49·7%) in the control group and 360 (50·3%) in the intervention group. 284 (80·0%) participants in the control group and 253 (70·3%) in the intervention group completed follow-up at 8 months. At 8-month follow-up, 158 (62·5%) participants in the intervention group showed recovery from depression (PHQ-9 score <10) compared with 125 (44·0%) in the control group (adjusted odds ratio 2·16 [95% CI 1·47-3·18]; p<0·0001). These findings were maintained in the complete case analysis. No adverse events related to the intervention were observed. Interpretation: Although the COVID-19 pandemic altered delivery of the intervention, the low-intensity psychosocial intervention delivered mainly by non-mental health professionals was highly efficacious in improving recovery from depression in older adults in Brazil. Our results support a low-resource intervention that could be useful to reduce the treatment gap for depression among older people in other LMICs. Funding: São Paulo Research Foundation and Joint Global Health Trials (UK Department for International Development, Medical Research Council, and the Wellcome Trust).

The lancet. Healthy longevity · randomised controlled trial · 25 citationsread the source →

Dual-Process Bereavement Group Intervention (DPBGI) for Widowed Older Adults.

Background and objectives: To examine the primary and secondary outcomes of a theory-driven group bereavement intervention for widowed older adults through a cluster-randomized controlled trial. Research designs and methods: Twelve community centers providing health and social services for elderly people were randomly assigned to the experimental condition, the dual-process bereavement group intervention-Chinese (DPBGI-C) and to the control condition, the loss-oriented bereavement group intervention-Chinese (LOBGI-C). Both interventions comprised weekly, 2-hr sessions for 7 weeks followed by a 4-hr outing in the eighth week. Of 215 widowed older adults contacted and assessed, 125 eligible participants were interviewed three times-preintervention, postintervention, and at a 16-week follow-up-to assess complicated grief symptoms, anxiety, depression, loneliness, and social support. Results: Using intention-to-treat analysis, both interventions produced improvements in grief, depression, and social support, but effect sizes were larger with the DPBGI-C. The participants in the DPBGI-C condition also reported reduced anxiety, emotional loneliness, and social loneliness, whereas those in the LOBGI-C condition did not. There were interactions between intervention type and time with respect to grief, anxiety, emotional loneliness, and social loneliness. Discussion and implications: Although traditional LOBGI-C can help to reduce grief and depression in bereaved older adults, the DPBGI-C was found to be superior as it had a greater and more extensive impact on outcomes. This is the first study of the effectiveness of this evidence-based, theory-driven intervention for widowed Chinese older adults and has implications for theory building and practice.

The Gerontologist · randomised controlled trial · 38 citationsread the source →

Treatment efficacy and effectiveness in adults with major depressive disorder and childhood trauma history: a systematic review and meta-analysis.

Background: Childhood trauma is a common and potent risk factor for developing major depressive disorder in adulthood, associated with earlier onset, more chronic or recurrent symptoms, and greater probability of having comorbidities. Some studies indicate that evidence-based pharmacotherapies and psychotherapies for adult depression might be less efficacious in patients with a history of childhood trauma than patients without childhood trauma, but findings are inconsistent. Therefore, we examined whether individuals with major depressive disorder, including chronic forms of depression, and a reported history of childhood trauma, had more severe depressive symptoms before treatment, had more unfavourable treatment outcomes following active treatments, and were less likely to benefit from active treatments relative to a control condition, compared with individuals with depression without childhood trauma. Methods: We did a comprehensive meta-analysis (PROSPERO CRD42020220139). Study selection combined the search of bibliographical databases (PubMed, PsycINFO, and Embase) from Nov 21, 2013, to March 16, 2020, and full-text randomised clinical trials (RCTs) identified from several sources (1966 up to 2016-19) to identify articles in English. RCTs and open trials comparing the efficacy or effectiveness of evidence-based pharmacotherapy, psychotherapy, or combination intervention for adult patients with depressive disorders and the presence or absence of childhood trauma were included. Two independent researchers extracted study characteristics. Group data for effect-size calculations were requested from study authors. The primary outcome was depression severity change from baseline to the end of the acute treatment phase, expressed as standardised effect size (Hedges' g). Meta-analyses were done using random-effects models. Findings: From 10 505 publications, 54 trials met the inclusion criteria, of which 29 (20 RCTs and nine open trials) contributed data of a maximum of 6830 participants (age range 18-85 years, male and female individuals and specific ethnicity data unavailable). More than half (4268 [62%] of 6830) of patients with major depressive disorder reported a history of childhood trauma. Despite having more severe depression at baseline (g=0·202, 95% CI 0·145 to 0·258, I2=0%), patients with childhood trauma benefitted from active treatment similarly to patients without childhood trauma history (treatment effect difference between groups g=0·016, -0·094 to 0·125, I2=44·3%), with no significant difference in active treatment effects (vs control condition) between individuals with and without childhood trauma (childhood trauma g=0·605, 0·294 to 0·916, I2=58·0%; no childhood trauma g=0·178, -0·195 to 0·552, I2=67·5%; between-group difference p=0·051), and similar dropout rates (risk ratio 1·063, 0·945 to 1·195, I2=0%). Findings did not significantly differ by childhood trauma type, study design, depression diagnosis, assessment method of childhood trauma, study quality, year, or treatment type or length, but differed by country (North American studies showed larger treatment effects for patients with childhood trauma; false discovery rate corrected p=0·0080). Most studies had a moderate to high risk of bias (21 [72%] of 29), but the sensitivity analysis in low-bias studies yielded similar findings to when all studies were included. Interpretation: Contrary to previous studies, we found evidence that the symptoms of patients with major depressive disorder and childhood trauma significantly improve after pharmacological and psychotherapeutic treatments, notwithstanding their higher severity of depressive symptoms. Evidence-based psychotherapy and pharmacotherapy should be offered to patients with major depressive disorder regardless of childhood trauma status. Funding: None.

The lancet. Psychiatry · meta-analysis · 65 citationsread the source →

3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for post-traumatic stress disorder in military veterans, firefighters, and police officers: a randomised, double-blind, dose-response, phase 2 clinical trial.

Background: Post-traumatic stress disorder (PTSD) is prevalent in military personnel and first responders, many of whom do not respond to currently available treatments. This study aimed to assess the efficacy and safety of 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for treating chronic PTSD in this population. Methods: We did a randomised, double-blind, dose-response, phase 2 trial at an outpatient psychiatric clinic in the USA. We included service personnel who were 18 years or older, with chronic PTSD duration of 6 months or more, and who had a Clinician-Administered PTSD Scale (CAPS-IV) total score of 50 or greater. Using a web-based randomisation system, we randomly assigned participants (1:1:2) to three different dose groups of MDMA plus psychotherapy: 30 mg (active control), 75 mg, or 125 mg. We masked investigators, independent outcome raters, and participants until after the primary endpoint. MDMA was administered orally in two 8-h sessions with concomitant manualised psychotherapy. The primary outcome was mean change in CAPS-IV total score from baseline to 1 month after the second experimental session. Participants in the 30 mg and 75 mg groups subsequently underwent three 100-125 mg MDMA-assisted psychotherapy sessions in an open-label crossover, and all participants were assessed 12 months after the last MDMA session. Safety was monitored through adverse events, spontaneously reported expected reactions, vital signs, and suicidal ideation and behaviour. This study is registered with ClinicalTrials.gov, number NCT01211405. Findings: Between Nov 10, 2010, and Jan 29, 2015, 26 veterans and first responders met eligibility criteria and were randomly assigned to receive 30 mg (n=7), 75 mg (n=7), or 125 mg (n=12) of MDMA plus psychotherapy. At the primary endpoint, the 75 mg and 125 mg groups had significantly greater decreases in PTSD symptom severity (mean change CAPS-IV total scores of -58·3 [SD 9·8] and -44·3 [28·7]; p=0·001) than the 30 mg group (-11·4 [12·7]). Compared with the 30 mg group, Cohen's d effect sizes were large: 2·8 (95% CI 1·19-4·39) for the 75 mg group and 1·1 (0·04-2·08) for the 125 mg group. In the open-label crossover with full-dose MDMA (100-125 mg), PTSD symptom severity significantly decreased in the group that had previously received 30 mg (p=0·01), whereas no further significant decreases were observed in the group that previously achieved a large response after 75 mg doses in the blinded segment (p=0·81). PTSD symptoms were significantly reduced at the 12-month follow-up compared with baseline after all groups had full-dose MDMA (mean CAPS-IV total score of 38·8 [SD 28·1] vs 87·1 [16·1]; p<0·0001). 85 adverse events were reported by 20 participants. Of these adverse events, four (5%) were serious: three were deemed unrelated and one possibly related to study drug treatment. Interpretation: Active doses (75 mg and 125 mg) of MDMA with adjunctive psychotherapy in a controlled setting were effective and well tolerated in reducing PTSD symptoms in veterans and first responders. Funding: Multidisciplinary Association for Psychedelic Studies.

The lancet. Psychiatry · randomised controlled trial · 258 citationsread the source →

Efficacy and safety of the muscarinic receptor agonist KarXT (xanomeline-trospium) in schizophrenia (EMERGENT-2) in the USA: results from a randomised, double-blind, placebo-controlled, flexible-dose phase 3 trial.

Background: New treatments with new mechanisms are urgently needed for people with schizophrenia. Xanomeline is a dual M1 and M4-preferring muscarinic receptor agonist that does not block D2 dopamine receptors, unlike all currently approved treatments for schizophrenia. Xanomeline-trospium (KarXT) combines xanomeline with the peripherally restricted muscarinic receptor antagonist trospium chloride with the goal of ameliorating xanomeline-related adverse events associated with peripheral muscarinic receptors. The EMERGENT-2 trial aimed to assess the efficacy and safety of KarXT in people with schizophrenia experiencing acute psychosis. Methods: EMERGENT-2 was a randomised, double-blind, placebo-controlled, flexible-dose, 5-week, inpatient, phase 3 trial in people with schizophrenia. Participants were adults aged 18-65 years with a diagnosis of schizophrenia who had a recent worsening of psychosis warranting hospital admission, a Positive and Negative Syndrome Scale (PANSS) score of 80 or higher, and a Clinical Global Impression-Severity score of 4 or higher. The participants were recruited from 22 inpatient sites in the USA, and were randomly assigned (1:1) to KarXT or placebo twice per day. Participants randomly assigned to KarXT received 50 mg xanomeline and 20 mg trospium twice per day for the first 2 days and then 100 mg xanomeline and 20 mg trospium twice per day for days 3-7. Beginning on day 8, KarXT dosing was flexible with an optional increase to 125 mg xanomeline and 30 mg trospium twice per day and the option to return to 100 mg xanomeline and 20 mg trospium based on tolerability. The primary endpoint was change from baseline to week 5 in PANSS total score. Efficacy analyses used the modified intention-to-treat population (all randomly assigned participants who received at least one trial medication dose and had at least one post-baseline PANSS assessment). Least squares mean change from baseline, SE, and least squares mean difference between the KarXT and placebo groups at week 5, along with the 95% CI and two-sided p values were calculated for the primary and secondary continuous efficacy endpoints. Safety analyses included all participants receiving at least one trial medication dose and used descriptive statistics. This trial is registered with ClinicalTrials.gov (NCT04659161). Findings: From Dec 16, 2020, to April 13, 2022, of 407 people who were screened, 252 participants meeting enrolment criteria were randomly assigned to the KarXT (n=126) or placebo (n=126). Baseline PANSS total scores were 98·3 (KarXT; n=126) and 97·9 (placebo; n=125). The trial met the primary endpoint with a mean change from baseline to week 5 in PANSS total score that favoured KarXT (-21·2 points, SE 1·7) versus placebo (-11·6 points, 1·6; least squares mean difference -9·6; 95% CI -13·9 to -5·2; p<0·0001, Cohen's d effect size=0·61). All secondary endpoints were also met, and favoured KarXT versus placebo (p<0·05). The most common adverse events with KarXT versus placebo were constipation (27 [21%] vs 13 [10%]), dyspepsia (24 [19%] vs 10 [8%]), headache (17 [14%] vs 15 [12%]), nausea (24 [19%] vs seven [6%]), vomiting (18 [14%] vs one [1%]), hypertension (12 [10%] vs one [1%]), dizziness (11 [9%] vs four [3%]), gastro-oesophageal reflux disease (eight [6%] vs zero [0%]), and diarrhoea (seven [6%] vs four [3%]). Treatment-emergent adverse event rates of extrapyramidal motor symptoms (KarXT, zero [0%] vs placebo, zero [0%]), akathisia (one [1%] vs one [1%]), weight gain (zero [0%] vs one [1%]), and somnolence (six [5%] vs five [4%]) were similar between the KarXT and placebo groups, as were adverse event-related discontinuation rates (nine [7%] vs seven [6%]). Interpretation: In the EMERGENT-2 trial, KarXT was effective in reducing positive and negative symptoms and was generally well tolerated. These results support the potential for KarXT to represent a new class of effective and well tolerated antipsychotic medicines based on activating muscarinic receptors, not the D2 dopamine receptor-blocking mechanism of all current antipsychotic medications. Results from additional trials, including the identical EMERGENT-3 trial and the 52-week, open-label EMERGENT-4 and EMERGENT-5 trials, will provide additional information on the efficacy and safety of KarXT in people with schizophrenia. Funding: Karuna Therapeutics.

Lancet (London, England) · randomised controlled trial · 144 citationsread the source →

Effectiveness of a brief lay counsellor-delivered, problem-solving intervention for adolescent mental health problems in urban, low-income schools in India: a randomised controlled trial.

Background: Mental health problems are a leading cause of disability in adolescents worldwide. Problem solving is a well-tested mental health intervention in many populations. We aimed to investigate the effectiveness of a brief, transdiagnostic problem-solving intervention for common adolescent mental health problems when delivered by non-specialist school counsellors in New Delhi, India. Methods: This randomised trial was done in six government-run schools (three all-boys schools, two all-girls schools, and one co-educational school) that serve low-income communities. We recruited participants from grades 9 to 12 (ages 12-20 years) by selecting students with persistently elevated mental health symptoms accompanied by distress or functional impairment. Clinical eligibility criteria were assessed by research assistants using the Hindi-language version of the Strengths and Difficulties Questionnaire (SDQ), with reference to locally validated borderline cutoff scores of 19 or greater for boys and 20 or greater for girls on the SDQ Total Difficulties scale, an abnormal score of 2 or more on the SDQ Impact scale, and persistence of more than 1 month on the SDQ Chronicity index. Participants were randomly allocated (1:1) to problem solving delivered through a brief (2-3 week) counsellor-led intervention with supporting printed materials (intervention group), or problem solving delivered via printed booklets alone (control group). Primary outcomes were adolescent-reported mental health symptoms (SDQ Total Difficulties scale) and idiographic psychosocial problems (Youth Top Problems [YTP]) at 6 weeks. Primary analyses were done on an intention-to-treat basis at the 6-week endpoint. The trial is registered with ClinicalTrials.gov, NCT03630471. Findings: Participants were enrolled between Aug 20, and Dec 4, 2018. 283 eligible adolescents were referred to the trial, and 251 (89%) of these were enrolled (mean age 15·61 years; 174 [69%] boys). 125 participants were allocated to each group (after accounting for one participant in the intervention group who withdrew consent after randomisation). Primary outcome data were available for 245 (98%) participants. At 6 weeks, the mean YTP scores were 3·52 (SD 2·66) in the intervention group and 4·60 (2·75) in the control group (adjusted mean difference -1·01, 95% CI -1·63 to -0·38; adjusted effect size 0·36, 95% CI 0·11 to 0·61; p=0·0015). The mean SDQ Total Difficulties scores were 17·48 (5·45) in the intervention group and 18·33 (5·45) in the control group (-0·86, -2·14 to 0·41; 0·16, -0·09 to 0·41; p=0·18). We observed no adverse events. Interpretation: A brief lay counsellor-delivered problem-solving intervention combined with printed booklets seemed to have a modest effect on psychosocial outcomes among adolescents with diverse mental health problems compared with problem-solving booklets alone. This counsellor-delivered intervention might be a suitable first-line intervention in a stepped care approach, which is being evaluated in ongoing studies. Funding: Wellcome Trust.

The Lancet. Child & adolescent health · randomised controlled trial · 69 citationsread the source →

Efficacy and Safety of Xanomeline-Trospium Chloride in Schizophrenia: A Randomized Clinical Trial.

Importance: A significant need exists for new antipsychotic medications with different mechanisms of action, greater efficacy, and better tolerability than existing agents. Xanomeline is a dual M1/M4 preferring muscarinic receptor agonist with no direct D2 dopamine receptor blocking activity. KarXT combines xanomeline with the peripheral muscarinic receptor antagonist trospium chloride with the goal of reducing adverse events due to xanomeline-related peripheral muscarinic receptor activation. In prior trials, xanomeline-trospium chloride was effective in reducing symptoms of psychosis and generally well tolerated in people with schizophrenia. Objective: To evaluate the efficacy and safety of xanomeline-trospium vs placebo in adults with schizophrenia. Design, setting, and participants: EMERGENT-3 (NCT04738123) was a phase 3, multicenter, randomized, double-blind, placebo-controlled, 5-week trial of xanomeline-trospium in people with schizophrenia experiencing acute psychosis, conducted between April 1, 2021, and December 7, 2022, at 30 inpatient sites in the US and Ukraine. Data were analyzed from February to June 2023. Interventions: Participants were randomized 1:1 to receive xanomeline-trospium chloride (maximum dose xanomeline 125 mg/trospium 30 mg) or placebo for 5 weeks. Main outcomes and measures: The prespecified primary end point was change from baseline to week 5 in Positive and Negative Syndrome Scale (PANSS) total score. Secondary outcome measures were change from baseline to week 5 in PANSS positive subscale score, PANSS negative subscale score, PANSS Marder negative factor score, Clinical Global Impression-Severity score, and proportion of participants with at least a 30% reduction in PANSS total score. Safety and tolerability were also evaluated. Results: A total of 256 participants (mean [SD] age, 43.1 [11.8] years; 191 men [74.6%]; 156 of 256 participants [60.9%] were Black or African American, 98 [38.3%] were White, and 1 [0.4%] was Asian) were randomized (125 in xanomeline-trospium group and 131 in placebo group). At week 5, xanomeline-trospium significantly reduced PANSS total score compared with placebo (xanomeline-trospium , -20.6; placebo, -12.2; least squares mean difference, -8.4; 95% CI, -12.4 to -4.3; P < .001; Cohen d effect size, 0.60). Discontinuation rates due to treatment-emergent adverse events (TEAEs) were similar between the xanomeline-trospium (8 participants [6.4%]) and placebo (7 participants [5.5%]) groups. The most common TEAEs in the xanomeline-trospium vs placebo group were nausea (24 participants [19.2%] vs 2 participants [1.6%]), dyspepsia (20 participants [16.0%] vs 2 participants [1.6%]), vomiting (20 participants [16.0%] vs 1 participant [0.8%]), and constipation (16 participants [12.8%] vs 5 participants [3.9%]). Measures of extrapyramidal symptoms, weight gain, and somnolence were similar between treatment groups. Conclusions and relevance: Xanomeline-trospium was efficacious and well tolerated in people with schizophrenia experiencing acute psychosis. These findings, together with the previously reported and consistent results from the EMERGENT-1 and EMERGENT-2 trials, support the potential of xanomeline-trospium to be the first in a putative new class of antipsychotic medications without D2 dopamine receptor blocking activity. Trial registration: ClinicalTrials.gov Identifier: NCT04738123.

JAMA psychiatry · randomised controlled trial · 128 citationsread the source →

Relaxin for the treatment of patients with acute heart failure (Pre-RELAX-AHF): a multicentre, randomised, placebo-controlled, parallel-group, dose-finding phase IIb study.

Background: Most patients admitted for acute heart failure have normal or increase blood pressure. Relaxin is a natural human peptide that affects multiple vascular control pathways, suggesting potential mechanisms of benefit for such patients. We assessed the dose response of relaxin's effect on symptom relief, other clinical outcomes, and safety. Methods: In a placebo-controlled, parallel-group, dose-ranging study, 234 patients with acute heart failure, dyspnoea, congestion on chest radiograph, and increased brain natriuretic peptide (BNP) or N-terminal prohormone of BNP, mild-to-moderate renal insufficiency, and systolic blood pressure greater than 125 mm Hg were recruited from 54 sites in eight countries and enrolled within 16 h of presentation. Patients were randomly assigned, in a double-blind manner via a telephone-based interactive voice response system, to standard care plus 48-h intravenous infusion of placebo (n=62) or relaxin 10 microg/kg (n=40), 30 microg/kg (n=43), 100 microg/kg (n=39), or 250 microg/kg (n=50) per day. Several clinical endpoints were explored to assess whether intravenous relaxin should be pursued in larger studies of acute heart failure, to identify an optimum dose, and to help to assess endpoint selection and power calculations. Analysis was by modified intention to treat. This study is registered with ClinicalTrials.gov, number NCT00520806. Findings: In the modified intention-to-treat population, 61 patients were assessed in the placebo group, 40 in the relaxin 10 microg/kg per day group, 42 in the relaxin 30 microg/kg per day group, 37 in the relaxin 100 microg/kg per day group, and 49 in the relaxin 250 microg/kg per day group. Dyspnoea improved with relaxin 30 microg/kg compared with placebo, as assessed by Likert scale (17 of 42 patients [40%] moderately or markedly improved at 6 h, 12 h, and 24 h vs 14 of 61 [23%]; p=0.044) and visual analogue scale through day 14 (8214 mm x h [SD 8712] vs 4622 mm x h [9003]; p=0.053). Length of stay was 10.2 days (SD 6.1) for relaxin-treated patients versus 12.0 days (7.3) for those given placebo, and days alive out of hospital were 47.9 (10.1) versus 44.2 (14.2). Cardiovascular death or readmission due to heart or renal failure at day 60 was reduced with relaxin (2.6% [95% CI 0.4-16.8] vs 17.2% [9.6-29.6]; p=0.053). The number of serious adverse events was similar between groups. Interpretation: When given to patients with acute heart failure and normal-to-increased blood pressure, relaxin was associated with favourable relief of dyspnoea and other clinical outcomes, with acceptable safety.

Lancet (London, England) · randomised controlled trial · 314 citationsread the source →

Domestic violence and perinatal mental disorders: a systematic review and meta-analysis.

Background: Domestic violence in the perinatal period is associated with adverse obstetric outcomes, but evidence is limited on its association with perinatal mental disorders. We aimed to estimate the prevalence and odds of having experienced domestic violence among women with antenatal and postnatal mental disorders (depression and anxiety disorders including post-traumatic stress disorder [PTSD], eating disorders, and psychoses). Methods and findings: We conducted a systematic review and meta-analysis (PROSPERO reference CRD42012002048). Data sources included searches of electronic databases (to 15 February 2013), hand searches, citation tracking, update of a review on victimisation and mental disorder, and expert recommendations. Included studies were peer-reviewed experimental or observational studies that reported on women aged 16 y or older, that assessed the prevalence and/or odds of having experienced domestic violence, and that assessed symptoms of perinatal mental disorder using a validated instrument. Two reviewers screened 1,125 full-text papers, extracted data, and independently appraised study quality. Odds ratios were pooled using meta-analysis. Sixty-seven papers were included. Pooled estimates from longitudinal studies suggest a 3-fold increase in the odds of high levels of depressive symptoms in the postnatal period after having experienced partner violence during pregnancy (odds ratio 3.1, 95% CI 2.7-3.6). Increased odds of having experienced domestic violence among women with high levels of depressive, anxiety, and PTSD symptoms in the antenatal and postnatal periods were consistently reported in cross-sectional studies. No studies were identified on eating disorders or puerperal psychosis. Analyses were limited because of study heterogeneity and lack of data on baseline symptoms, preventing clear findings on causal directionality. Conclusions: High levels of symptoms of perinatal depression, anxiety, and PTSD are significantly associated with having experienced domestic violence. High-quality evidence is now needed on how maternity and mental health services should address domestic violence and improve health outcomes for women and their infants in the perinatal period.

PLoS medicine · meta-analysis · 292 citationsread the source →

A randomized controlled trial of a couple relationship and coparenting program (Couple CARE for Parents) for high- and low-risk new parents.

Objective: This study evaluated the effectiveness of couple relationship education in assisting couples to sustain relationship functioning and parenting sensitivity, and whether benefits were moderated by risk of maladjustment in the transition to parenthood ("risk"). Method: Two hundred fifty couples expecting their first child were assessed on risk and randomly assigned to either the Couple CARE for Parents (CCP), a couple relationship- and coparenting-focused education program (n = 125), or the Becoming a Parent Program (BAP), a mother-focused parenting program (n = 125). Couples completed assessments of their couple relationship during pregnancy, after intervention at 4 months postpartum, and at 16 and 28 months postpartum. Observed parenting and self-report parenting stress were assessed at 4 months postpartum, and parenting stress was assessed again at 16 and 28 months postpartum. Results: Risk was associated with greater relationship and parenting adjustment problems. Relative to BAP, CCP women decreased their negative communication and showed a trend to report less parenting stress irrespective of risk level. High-risk women receiving CCP reported higher relationship satisfaction, and were less intrusive in their parenting, than high-risk women receiving BAP. There were no effects of CCP on sensitive parenting and parenting intrusiveness for women. High-risk men in CCP showed a trend for higher relationship satisfaction than high-risk BAP men, but there were no effects of CCP for men on any parenting outcomes. Conclusions: CCP is a potentially useful intervention, but benefits are primarily for high-risk women.

Journal of consulting and clinical psychology · randomised controlled trial · 38 citationsread the source →

The role of parenting, attachment, and temperamental fearfulness in the prediction of compliance in toddler girls

The development, antecedents, and concomitants of committed compliance in the second year of life were investigated, with a special emphasis on the influences of parental discipline and sensitivity, attachment security, and temperamental fearfulness. At 16 and at 22 months, 125 first‐born girls from middle‐class families were observed in their homes and in the laboratory. Committed compliance was assessed in a clean‐up task ('do' task), and in a task in which the children were asked to refrain from touching attractive toys ('don't' task). Temperamental fearfulness was observed when the children were confronted with seven somewhat scary items, such as a stethoscope and a rubber bird of prey. Attachment security was assessed with the Strange Situation procedure, and parental discipline and sensitivity measures were derived from home and lab observations in problem‐solving and limit‐setting situations. Maternal sensitivity during a puzzle task was related to more compliance of the child to her prohibitions, and maternal intrusiveness was associated with less compliance to maternal requests. Committed compliance was associated with concurrent parenting, attachment, and temperament. Controlling for concurrent parenting, attachment, and temperament, we did not find any significant associations between antecedent parenting and later compliance. Our data failed to support Kochanska's (1995, 1997) model of the impact of antecedent socialization and temperament on emergent morality.

British Journal of Developmental Psychology · 84 citationsread the source →

Development of Empathy in Girls During the Second Year of Life: Associations with Parenting, Attachment, and Temperament

The development, antecedents, and concomitants of empathic concern in the second year of life were examined. Associations with parental sensitivity, children's fearfulness and attachment security were investigated. At 16 and at 22 months, 125 firstborn girls from middle‐class families were observed in their homes and in the laboratory. Empathic concern was assessed from the girls’ responses to simulated distress in their mothers and in an unfamiliar person. Temperamental fearfulness was observed when they were confronted with potentially scary items. Attachment security was assessed with the Strange Situation procedure, and parental sensitivity was measured in problem‐solving situations both at home and in the lab. From 16 to 22 months, empathic concern for the mother's distress increased, whereas empathy for the stranger decreased. A more fearful temperament and less attachment security predicted less empathic concern for the stranger's distress. Antecedent and concurrent measures of parenting showed disappointingly weak associations with empathic concern. Empathy for strangers in distress requires the regulation of negative emotions for which fearful and insecurely attached girls seem to be less well equipped.

Social Development · 177 citationsread the source →

Symptom recognition and help seeking for depression in young adults: a vignette study.

Purpose: Many young people with psychological problems do not seek help. Recognition of problems and knowledge of appropriate sources of help may increase the likelihood of help seeking. This study aimed to explore whether young adults recognised depressive symptoms in a vignette, and how they thought a young person might respond to these symptoms. Methods: A postal survey was sent to 3,004 young people aged 16-24 in SW England. The survey included a two-part vignette; the first part depicted mild depressive symptoms, and the second part depicted severe depressive symptoms. Open-ended questions exploring symptom recognition and illness behaviour were answered by 1,125 respondents. Results: Severe depressive symptoms were recognised by 61.4% of respondents. Young men, particularly those from deprived backgrounds were less likely than women to recognise a mental health problem. Men were also less likely to suggest seeing a doctor than women. 64.7% of the respondents who recognised a mental health problem suggested seeing a doctor, however, only 16.4% thought a severely depressed person actually would see a doctor. Conclusions: Whilst the majority of young people recognised symptoms of severe depression, the gap between perceived options for help and proposed help seeking behaviour is clinically relevant. The sociodemographic groups at greatest risk of suicide are the least likely to recognise depression, highlighting a need to develop interventions targeting men, particularly those from deprived backgrounds.

Social psychiatry and psychiatric epidemiology · cohort or longitudinal · 29 citationsread the source →

Hope for the Best, and Prepare for the Worst

Medical Writings4 March 2003Hope for the Best, and Prepare for the WorstAnthony L. Back, MD, Robert M. Arnold, MD, and Timothy E. Quill, MDAnthony L. Back, MDFrom Veterans Administration Puget Sound Health Care System, University of Washington, Seattle, Washington; University of Pittsburgh, Pittsburgh, Pennsylvania; University of Rochester, Rochester, New York., Robert M. Arnold, MDFrom Veterans Administration Puget Sound Health Care System, University of Washington, Seattle, Washington; University of Pittsburgh, Pittsburgh, Pennsylvania; University of Rochester, Rochester, New York., and Timothy E. Quill, MDFrom Veterans Administration Puget Sound Health Care System, University of Washington, Seattle, Washington; University of Pittsburgh, Pittsburgh, Pennsylvania; University of Rochester, Rochester, New York. Author, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-138-5-200303040-00028 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Mr. J., a 40-year-old father of two young children, has metastatic non–small-cell lung cancer that has not responded to two different chemotherapy regimens. His physician, Dr. B., explains that the cancer is progressing. Mr. J. says, Isn't there something you can do? Please don't give up on me. Dr. B. pauses and says, Well, there is an experimental protocol we could try. When faced with life-threatening illness, patients and physicians often feel that they must choose between hoping for disease remission and preparing for death. Mr. J. wants to fight the cancer in hope of living longer, and his physician ...References1. Delvecchio Good MJ, Good BJ, Schaffer C, Lind SE. American oncology and the discourse on hope. Cult Med Psychiatry. 1990;14:59-79. [PMID: 2340733] CrossrefMedlineGoogle Scholar2. The AM, Hak T, Koter G, van Der Wal G. Collusion in doctor-patient communication about imminent death: an ethnographic study. BMJ. 2000;321:1376-81. [PMID: 11099281] CrossrefMedlineGoogle Scholar3. Ersek M, Kraybill BM, Pen AD. Factors hindering patients' use of medications for cancer pain. Cancer Pract. 1999;7:226-32. [PMID: 10687591] CrossrefMedlineGoogle Scholar4. Cleeland CS, Gonin R, Hatfield AK, Edmonson JH, Blum RH, Stewart JA, . Pain and its treatment in outpatients with metastatic cancer. N Engl J Med. 1994;330:592-6. [PMID: 7508092] CrossrefMedlineGoogle Scholar5. Byock IR. The nature of suffering and the nature of opportunity at the end of life. Clin Geriatr Med. 1996;12:237-52. [PMID: 8799345] CrossrefMedlineGoogle Scholar6. Glaser BG, Strauss AL. Awareness of Dying. Chicago: Aldine Publishing; 1965. Google Scholar7. Kubler-Ross E. On Death and Dying. New York: Macmillan; 1969. Google Scholar8. Weisman A. On Dying and Denying: A Psychiatric Study of Terminality. New York: Behavioral Publications; 1972. Google Scholar9. McCormick TR, Conley BJ. Patients' perspectives on dying and on the care of dying patients. West J Med. 1995;163:236-43. [PMID: 7571586] MedlineGoogle Scholar10. Barnard D, Boston P, Towers AM, Lambrinidou Y. Crossing over: Narratives of Palliative Care. New York: Oxford Univ Pr; 2000. Google Scholar11. Kuhl D. What Dying People Want: Practical Wisdom for the End of Life. New York: PublicAffairs; 2002. Google Scholar12. Herth K. Fostering hope in terminally-ill people. J Adv Nurs. 1990;15:1250-9. [PMID: 2269747] CrossrefMedlineGoogle Scholar13. Quill TE, Cassel CK. Nonabandonment: a central obligation for physicians. Ann Intern Med. 1995;122:368-74. [PMID: 7847649] LinkGoogle Scholar14. Crawshaw R, Rogers DE, Pellegrino ED, Bulger RJ, Lundberg GD, Bristow LR, . Patient-physician covenant. JAMA. 1995;273:1553. [PMID: 7739086] CrossrefMedlineGoogle Scholar15. Maguire P. Improving communication with cancer patients. Eur J Cancer. 1999;35:1415-22. [PMID: 10673972] CrossrefMedlineGoogle Scholar16. Steinhauser KE, Christakis NA, Clipp EC, McNeilly M, McIntyre L, Tulsky JA. Factors considered important at the end of life by patients, family, physicians, and other care providers. JAMA. 2000;284:2476-82. [PMID: 11074777] CrossrefMedlineGoogle Scholar17. Singer PA, Martin DK, Kelner M. Quality end-of-life care: patients' perspectives. JAMA. 1999;281:163-8. [PMID: 9917120] CrossrefMedlineGoogle Scholar18. Heaven CM, Maguire P. Disclosure of concerns by hospice patients and their identification by nurses. Palliat Med. 1997;11:283-90. [PMID: 9373579] CrossrefMedlineGoogle Scholar19. Quill TE. Recognizing and adjusting to barriers in doctor-patient communication. Ann Intern Med. 1989;111:51-7. [PMID: 2660647] LinkGoogle Scholar20. Quill TE, Brody H. Physician recommendations and patient autonomy: finding a balance between physician power and patient choice. Ann Intern Med. 1996;125:763-9. [PMID: 8929011] LinkGoogle Scholar21. Curtis JR, Wenrich MD, Carline JD, Shannon SE, Ambrozy DM, Ramsey PG. Understanding physicians' skills at providing end-of-life care perspectives of patients, families, and health care workers. J Gen Intern Med. 2001;16:41-9. [PMID: 11251749] MedlineGoogle Scholar22. Quill TE, Suchman AL. Uncertainty and control: learning to live with medicine's limitations. Humane Med. 1993;9:109-20. [PMID: 11656250] MedlineGoogle Scholar23. Meier DE, Back AL, Morrison RS. The inner life of physicians and care of the seriously ill. JAMA. 2001;286:3007-14. [PMID: 11743845] CrossrefMedlineGoogle Scholar24. Lamont EB, Christakis NA. Prognostic disclosure to patients with cancer near the end of life. Ann Intern Med. 2001;134:1096-105. [PMID: 11412049] LinkGoogle Scholar25. Weeks JC, Cook EF, O'Day SJ, Peterson LM, Wenger N, Reding D, . Relationship between cancer patients' predictions of prognosis and their treatment preferences. JAMA. 1998;279:1709-14. [PMID: 9624023] CrossrefMedlineGoogle Scholar26. Emanuel EJ, Young-Xu Y, Ash A, Gazelle G, Levinsky N, Moskowitz M. How much chemotherapy are cancer patients receiving at the end of life? [Abstract] Proceedings of the 37th Annual Meeting of the American Society of Clinical Oncology, San Francisco, CA; 1215 May 2001. Abstract no. 953. Google Scholar27. Shapiro A. The Vigil. Chicago: Univ of Chicago Pr; 1997. Google Scholar28. Waisel DB. The hazards of hanging crepe or stating overly pessimistic prognoses. J Clin Ethics. 2000;11:171-4. [PMID: 11056876] MedlineGoogle Scholar29. Siegler M. Remarks on crepe hangingor ethics in everyday practice. Am Med News. 1977;20:22. [PMID: 11664719] MedlineGoogle Scholar30. Kagawa-Singer M, Blackhall LJ. Negotiating cross-cultural issues at the end of life: You got to go where he lives. JAMA. 2001;286:2993-3001. [PMID: 11743841] CrossrefMedlineGoogle Scholar31. Crawley L, Payne R, Bolden J, Payne T, Washington P, Williams S, . Palliative and end-of-life care in the African American community. JAMA. 2000;284:2518-21. [PMID: 11074786] CrossrefMedlineGoogle Scholar32. Quill TE, Williamson PR. Healthy approaches to physician stress. Arch Intern Med. 1990;150:1857-61. [PMID: 2393317] CrossrefMedlineGoogle Scholar33. Remen RN. Recapturing the soul of medicine: physicians need to reclaim meaning in their working lives. West J Med. 2001;174:4-5. [PMID: 11154646] CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAffiliations: From Veterans Administration Puget Sound Health Care System, University of Washington, Seattle, Washington; University of Pittsburgh, Pittsburgh, Pennsylvania; University of Rochester, Rochester, New York. Acknowledgments: The authors thank Dr. Susan Block for her helpful suggestions about the role of ambivalence. Grant Support: Drs. Back and Arnold are Faculty Scholars of the Project on Death in America. Dr. Arnold was also supported by the Greenwall Foundation, Ladies Hospital Aid Society of Western Pennsylvania, and the LAS Trust Foundation. Corresponding Author: Anthony Back, MD, Veterans Administration Puget Sound Health Care System, 1660 South Columbian Way S111, Seattle, WA 98108; e-mail, [email protected]washington.edu. Current Author Addresses: Dr. Back: Veterans Administration Puget Sound Health Care System, 1660 South Columbian Way S111, Seattle, WA 98108.Dr. Arnold: Section of Palliative Care and Medical Ethics, MUH 200 Lothrop Street 932, Pittsburgh, PA 15213.Dr. Quill: Palliative Care Program, University of Rochester School of Medicine, Box 601, 601 Elmwood Avenue, Rochester, NY 14642. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoHope for the Best, and Prepare for the Worst James D. Brody Metrics Cited byThe New Oncologic Diagnosis Discussion: Perspectives of Pediatric OncologistsPalliative care in neurological diseaseImplementation of a palliative care intervention for patients with COPD – a mixed methods process evaluation of the COMPASSION study"I Am Not the Same Man…": A Case Report of Management of Post-COVID Refractory DyspneaOutcomes of Immune Checkpoint Inhibitors in Patients with Cancer and a Poor Performance Status #445Pitfalls and Prospects — Lessons Learned from Early Palliative Care ResearchTaking a Chance to Recover: Families Look Back on the Decision to Pursue Tracheostomy After Severe Acute Brain InjuryCommunication Strategies When Patients Utilize Spiritual Language to Hope for a Miracle #433Communication and Conflict Resolution – Managing Conversations. A Culturally Sensitive ModelUnd wenn der Krebs doch wiederkommt? – Palliative Situation und VerlustPrognostication in dementiaPalliative care and its own identity, through an autoethnography: do you recognize these patterns?Hopeful dying? The meanings and practice of hope in palliative care family meetingsAdvance care planning in adult congenital heart disease: Unique approaches for a unique population3. Practice and Benefits of Advance Care PlanningCommunication principles and practices for making shared decisions about renal replacement therapy: a review of the literatureDevelopment of the Oncolo-GIST ("Giving Information Strategically & Transparently") Intervention Manual for Oncologist Skills Training in Advanced Cancer Prognostic Information CommunicationHope-Colored Glasses: Perceptions of Prognosis Among Pediatric Oncology Patients and Their ParentsJCS/JHFS 2021 Statement on Palliative Care in Cardiovascular DiseasesThe experiences and needs of couples affected by prostate cancer aged 65 and under: a qualitative studyRoles and Responsibilities of Nurses in Advance Care Planning in Palliative Care in the Acute Care SettingAdvance Care Planning – Vorausschauende VersorgungsplanungIllness and prognostic understanding in patients with hematologic malignanciesModels of Palliative Care Delivery for Individuals with Cystic Fibrosis: Cystic Fibrosis Foundation Evidence-Informed Consensus GuidelinesNonbeneficial Intensive Care: Misalignments Between Provider Assessments of Benefit and Use of Invasive TreatmentsThe considerations, experiences and support needs of family members making treatment decisions for patients admitted with major stroke: a qualitative studyEnd-of-life decision making in the context of chronic life-limiting disease: a concept analysis and conceptual modelHoping for the best, planning for the worst: Palliative care approach to Parkinson disease during the COVID-19 pandemicEnd-of-Life Care among US Adults with ESKD Who Were Waitlisted or Received a Kidney Transplant, 2005–2014Identifying Goals of CareChapitre 23. Soins palliatifs en cancérologiePalliative Care in Lung CancerPalliative Care in MCS Patients: Insights into Current Practice and OutcomesEnd of life care for patients with meningiomaDecision-Making about the Place of Death for Cancer Patients: A Concept AnalysisThirty Years Later: An Oncologist Reflects on Kübler-Ross's WorkReply to Hope, optimism, and the importance of caregivers in end‐of‐life careAdding a Wider Range and "Hope for the Best, and Prepare for the Worst" Statement: Preferences of Patients with Cancer for Prognostic CommunicationEmotions in the room: common emotional reactions to discussions of poor prognosis and tools to address themThe Use of Expectancy and Empathy When Communicating With Patients With Advanced Breast Cancer; an Observational Study of Clinician–Patient ConsultationsThe Effects of Adding Reassurance Statements: Cancer Patients' Preferences for Phrases in End-of-Life DiscussionsFinding Hope and Healing When Cure Is Not PossiblePalliative Care in the Intensive Care Unit (ICU)PrognosticationKommunikation, Partizipation, PatientenorientierungAdvance directives from haematology departments: the patient's freedom of choice and communication with families. A qualitative analysis of 35 written documentsQu'écrivent les personnes atteintes d'hémopathies malignes dans leurs directives anticipées ? Analyse qualitative de 35 écritsSupporting Family Decision-making for a Child Who Is Seriously Ill: Creating Synchrony and ConnectionHospice Use and Palliative Care for Patients With Heart FailureNICU Communication: The Many Disguises of OpportunityCommunication skills training for healthcare professionals working with people who have cancerKeeping Expectations in Check With Immune Checkpoint InhibitorsSources of parental hope in pediatric oncology"How Much Time Do I Have?": Communicating Prognosis in the Era of Exceptional RespondersWhen a Patient Is Reluctant To Talk About It: A Dual Framework To Focus on Living Well and Tolerate the Possibility of DyingDistress Due to Prognostic Uncertainty in Palliative Care: Frequency, Distribution, and Outcomes among Hospitalized Patients with Advanced CancerThree big things in neuropalliative care: Communication, personhood and uncertaintyAddressing a Patient's Hope for a MiraclePalliative Care in the Intensive Care Unit (ICU)Goals of Care and Difficult ConversationsPalliative Care for Geriatric Psychiatric Patients with Life-Limiting IllnessHope in the Context of Pain and Palliative CareSuffering, Hope, and HealingEnd of Life SupportPalliative and End-of-Life CareA Proposed Model for Perinatal Palliative CareHope and Uncertainty in the Age of MiraclesREMAP: A Framework for Goals of Care ConversationsQualitative Study on the Perceptions of Terminally Ill Cancer Patients and Their Family Members Regarding End-of-Life Experiences Focusing on Palliative SedationHow should realism and hope be combined in physician–patient communication at the end of life? An online focus-group study among participants with and without a Muslim backgroundPharmacological Management of People Living with End-Stage Chronic Obstructive Pulmonary DiseaseThe Liminal and the ParallaxIs There Hope? Is She There? How Families and Clinicians Experience Severe Acute Brain InjuryPalliative Care in Liver Transplantation: When to Consult a SpecialistEarly Palliative Care for Patients with Advanced CancerPalliative Care and End-of-Life Considerations in Patients with PAH–CHDCommunicationFamily discussions on life-sustaining interventions in neurocritical careA Singular Hope: How the Discussion Around Cancer Surgery Sometimes FailsCommunicating prognostic uncertainty in potential end-of-life contexts: experiences of family membersDirectives anticipées en dermato-oncologie : situation actuelle et perspectivesUsing a supportive care framework to understand and improve palliative care among cancer patients in AfricaInadequate Palliative Care in Chronic Lung Disease. An Issue of Health Care InequalityPalliative Care in Liver Transplantation, When to Consult a SpecialistPalliative Care and the Dying PatientDeeper Conversations Need Not Wait Until the EndPalliative CareAssessing Goals of CarePalliative Care for Patients with End-Stage Liver DiseaseCommunications by Professionals in Palliative CareCommunication with Older, Seriously Ill PatientsTeaching Colleagues How to Discuss Prognosis as Part of a Hospital-Wide Quality Improvement Project: The Positive Impact of a 90-Minute WorkshopParents' Faith and Hope during the Pediatric Palliative Phase and the Association with Long-Term Parental AdjustmentParental Hope for Children With Advanced CancerBreaking Bad News and Discussing Goals of Care in the Intensive Care UnitImproving End-of-Life Care Prognostic DiscussionsRespect des volontés en fin de vie : étude de faisabilité d'une information sur la personne de confiance et les directives anticipéesFrom hope to hope: The experience of older Chinese people with advanced cancerPreferences of Patients With Parkinson's Disease for Communication About Advanced Care PlanningPalliative Care and Hospice in Patients with Advanced Cardiovascular DiseasePalliative Care in Liver Transplantation, When to Consult a SpecialistEnd-of-Life Care and Treatment Preferences Among Adults with Congenital Heart DiseaseThe Changing Role of Palliative Care in the ICUCurrent State of the Art and Science of Patient-Clinician Communication in Progressive Disease: Patients' Need to Know and Need to Feel KnownA Communication Framework for Dialysis Decision-Making for Frail Elderly PatientsFamilies and the transition to specialist palliative careDying with Dignity in the Intensive Care UnitPalliative and End-of-Life Care in StrokeSoins palliatifs en cancérologieFactors influencing patients' hope in stroke and spinal cord injury: A narrative reviewMedicolegal aspects of treatment on the Intensive Care UnitCommunicating About Prognosis: Ethical Responsibilities of Pediatricians and ParentsCommunication Between Doctor and Cancer PatientManaging brain metastases patientswith and without radiotherapy: initial lessonsfrom a team-based consult service through a multidisciplinary integrated palliative oncology clinicParent perceptions of early prognostic encounters following children's severe traumatic brain injury: 'Locked up in this cage of absolute horror'Trajectory of parental hope when a child has difficult-to-treat cancer: a prospective qualitative study"In the Beginning . . . "'I don't want to burden my family': handling communication challenges in geriatric oncologyPalliative care for people with heart failure: Summary of current evidence and future directionEnd-of-Life Care Discussions in Patients With Advanced CancerPatient's expression of hope and illness narratives in three neurological conditions: a meta-ethnographyAcute Lung Injury and Acute Respiratory Distress Syndrome Requiring Tracheal Intubation and Mechanical Ventilation in the Intensive Care UnitCoping des patients atteints de cancer en phase palliative et communication médicaleThe Cultivation of Prognostic Awareness Through the Provision of Early Palliative Care in the Ambulatory Setting: A Communication GuideSurvival times of women with metastatic breast cancer starting first-line chemotherapy in routine clinical practice versus contemporary randomised trialsBreaking Bad News in Counseling: Applying the PEWTER Model in the School SettingLatent Classes of Prognosis Conversations in Palliative Care: A Mixed-Methods StudyImproving Oncology Nurses' Communication Skills for Difficult ConversationsBoth Maintaining Hope and Preparing for Death: Effects of Physicians' and Nurses' Behaviors From Bereaved Family Members' PerspectivesFamily involvement in the end-of-life decisions of competent intensive care patientsHope in the Context of Pain and Palliative CareSuffering, Hope, and HealingEthical Issues in Stroke PatientsBesonderheiten der pädiatrischen Palliativversorgung bei besonderen PatientengruppenWhat Is Known About Prognostication in Advanced Illness?What Special Considerations Are Needed for Treating Patients With Chronic Liver Disease?The meaning of cancer: implications for family finances and consequent impact on lifestyle, and Communication to hope is a Hope in the context of care Discussions for Patients With Life-Limiting Strategies for of the Kidney Disease by Elderly Patients and A Much a Family Meeting with an in with congenital heart disease: A for early of Patients with Ethical End-of-Life Issues in Patients with Lung Management and Palliative CareHope Is a and Decision The Need for a To Patient in Decision a need for pediatric palliative with Prognostic Disclosure of Families of Patients with Experiences of hope among cancer patients in palliative care planning in chronic disease: barriers and of about palliative care and end-of-life a of skills for care with heart a review and narrative Issues Among People Living With Advanced of Hope as a of Distress and Life in a of Cancer Hope and Prognostic Nurses' Perspectives on Their Role When Patients Life-Limiting and the of Hope in with Severe experience of the of in a When Discussing and Life with a A Is of qualitative study in neurological and hope: communication with in the for of and and Death: A of Dying Cancer Patients' Talk About care: on patient and family on and Practical to the Family a Decision in the in the practice of palliative of CarePalliative Care in Pediatric and Preparing for Death: Perspectives of Decision A. M. MD, MD, and B. MD, of in and Benefits of Early Phase Cancer What Do What Do Patients About Conversations at the End of Life Is the illness in the of of patients who in the intensive care Regarding Palliative and End-of-Life Care in Severe Chronic Obstructive Pulmonary Disease or Advanced by and for end-of-life care in the intensive care A by the American of Care der pädiatrischen Palliativversorgung bei besonderen and Prognostic in a A for to the Care in Advanced of Palliative Care of communication skills for oncology advanced practice about Lung Transplantation: of Patients and about lung needs of patients and support and Discussing Death in the A of Physician care and end-of-life decision in and palliative care Understanding the of With Ill Patients and care for patients with chronic About Prognosis Between and of Children With Preferences and the Impact of Prognostic Care and Intensive Care Unit Care: Care and Intensive Care Unit Care: Intensive Care Unit Care care: evaluation in clinical at of with and with Families in Palliative Care: Not for a to improve palliative care: Advanced heart Clinical and On a of Palliative Care: A for and on and en de la of Chinese Cancer Patients of the and by Their about Palliative Care for Patients with Chronic Obstructive Pulmonary or Not to Is the Pain When Pain and are family members with palliative care A qualitative and hope when the future with cancer patients and their Prognostic Communication With Advanced Cancer the End of the Relationship with Patients Who Are L. Back, MD, Robert M. Arnold, MD, James A. MD, MD, and A. Perceptions of and the of About the Communication Issues and issues to end‐of‐life careA conceptual framework for end-of-life care: A of influencing the of the about the of treatment and transition to palliative Years Later: An Oncologist Reflects on palliative and supportive care in advanced heart and Bad A Patient's for the Best, and Prepare for the D. Communication and Hope: Communication in Palliative Issues for the and Cancer and End-of-Life advanced care planning and of dying for people with of palliative care March Issue care March Issue March & by American of

Annals of Internal Medicine · case report · 366 citationsread the source →

Analysis of Plasma Cell-Free DNA by Ultradeep Sequencing in Patients With Stages I to III Colorectal Cancer.

Importance: Novel sensitive methods for detection and monitoring of residual disease can improve postoperative risk stratification with implications for patient selection for adjuvant chemotherapy (ACT), ACT duration, intensity of radiologic surveillance, and, ultimately, outcome for patients with colorectal cancer (CRC). Objective: To investigate the association of circulating tumor DNA (ctDNA) with recurrence using longitudinal data from ultradeep sequencing of plasma cell-free DNA in patients with CRC before and after surgery, during and after ACT, and during surveillance. Design, setting, and participants: In this prospective, multicenter cohort study, ctDNA was quantified in the preoperative and postoperative settings of stages I to III CRC by personalized multiplex, polymerase chain reaction-based, next-generation sequencing. The study enrolled 130 patients at the surgical departments of Aarhus University Hospital, Randers Hospital, and Herning Hospital in Denmark from May 1, 2014, to January 31, 2017. Plasma samples (n = 829) were collected before surgery, postoperatively at day 30, and every third month for up to 3 years. Main outcomes and measures: Outcomes were ctDNA measurement, clinical recurrence, and recurrence-free survival. Results: A total of 130 patients with stages I to III CRC (mean [SD] age, 67.9 [10.1] years; 74 [56.9%] male) were enrolled in the study; 5 patients discontinued participation, leaving 125 patients for analysis. Preoperatively, ctDNA was detectable in 108 of 122 patients (88.5%). After definitive treatment, longitudinal ctDNA analysis identified 14 of 16 relapses (87.5%). At postoperative day 30, ctDNA-positive patients were 7 times more likely to relapse than ctDNA-negative patients (hazard ratio [HR], 7.2; 95% CI, 2.7-19.0; P < .001). Similarly, shortly after ACT ctDNA-positive patients were 17 times (HR, 17.5; 95% CI, 5.4-56.5; P < .001) more likely to relapse. All 7 patients who were ctDNA positive after ACT experienced relapse. Monitoring during and after ACT indicated that 3 of the 10 ctDNA-positive patients (30.0%) were cleared by ACT. During surveillance after definitive therapy, ctDNA-positive patients were more than 40 times more likely to experience disease recurrence than ctDNA-negative patients (HR, 43.5; 95% CI, 9.8-193.5 P < .001). In all multivariate analyses, ctDNA status was independently associated with relapse after adjusting for known clinicopathologic risk factors. Serial ctDNA analyses revealed disease recurrence up to 16.5 months ahead of standard-of-care radiologic imaging (mean, 8.7 months; range, 0.8-16.5 months). Actionable mutations were identified in 81.8% of the ctDNA-positive relapse samples. Conclusions and relevance: Circulating tumor DNA analysis can potentially change the postoperative management of CRC by enabling risk stratification, ACT monitoring, and early relapse detection.

JAMA oncology · 763 citationsread the source →

Understanding nutrition, depression and mental illnesses

INTRODUCTION Few people are aware of the connection between nutrition and depression while they easily understand the connection between nutritional deficiencies and physical illness. Depression is more typically thought of as strictly biochemical-based or emotionally-rooted. On the contrary, nutrition can play a key role in the onset as well as severity and duration of depression. Many of the easily noticeable food patterns that precede depression are the same as those that occur during depression. These may include poor appetite, skipping meals, and a dominant desire for sweet foods.[1] Nutritional neuroscience is an emerging discipline shedding light on the fact that nutritional factors are intertwined with human cognition, behavior, and emotions. The most common mental disorders that are currently prevalent in numerous countries are depression, bipolar disorder, schizophrenia, and obsessive-compulsive disorder (OCD).[2] The dietary intake pattern of the general population in many Asian and American countries reflects that they are often deficient in many nutrients, especially essential vitamins, minerals, and omega-3 fatty acids.[3] A notable feature of the diets of patients suffering from mental disorders is the severity of deficiency in these nutrients.[3] Studies have indicated that daily supplements of vital nutrients are often effective in reducing patients' symptoms.[4] Supplements containing amino acids have also been found to reduce symptoms, as they are converted to neurotransmitters which in turn alleviate depression and other mental health problems.[4] On the basis of accumulating scientific evidence, an effective therapeutic intervention is emerging, namely nutritional supplement/treatment. These may be appropriate for controlling and to some extent, preventing depression, bipolar disorder, schizophrenia, eating disorders and anxiety disorders, attention deficit disorder/attention deficit hyperactivity disorder (ADD/ADHD), autism, and addiction.[4] Most prescription drugs, including the common antidepressants lead to side effects.[4] This usually causes the patients to skip taking their medications. Such noncompliance is a common occurrence encountered by psychiatrists. An important point to remember here is that, such noncompliant patients who have mental disorders are at a higher risk for committing suicide or being institutionalized. In some cases, chronic use or higher doses may lead to drug toxicity, which may become life threatening to the patient.[4] An alternate and effective way for psychiatrists to overcome this noncompliance is to familiarize themselves about alternative or complementary nutritional therapies. Although further research needs to be carried out to determine the best recommended doses of most nutritional supplements in the cases of certain nutrients, psychiatrists can recommend doses of dietary supplements based on previous and current efficacious studies and then adjust the doses based on the results obtained by closely observing the changes in the patient.[4] When we take a close look at the diet of depressed people, an interesting observation is that their nutrition is far from adequate. They make poor food choices and selecting foods that might actually contribute to depression. Recent evidence suggests a link between low levels of serotonin and suicide.[5] It is implicated that lower levels of this neurotransmitter can, in part, lead to an overall insensitivity to future consequences, triggering risky, impulsive and aggressive behaviors which may culminate in suicide, the ultimate act of inwardly directed impulsive aggression. Depression is a disorder associated with major symptoms such as increased sadness and anxiety, loss of appetite, depressed mood, and a loss of interest in pleasurable activities. If there is no timely therapeutic intervention, this disorder can lead to varied consequences. Patients who are suffering from depression exhibit suicidal tendency to a larger degree and hence are usually treated with antidepressants and/or psychotherapy.[6] Deficiencies in neurotransmitters such as serotonin, dopamine, noradrenaline, and γ-aminobutyric acid (GABA) are often associated with depression.[6–11] As reported in several studies, the amino acids tryptophan, tyrosine, phenylalanine, and methionine are often helpful in treating many mood disorders including depression.[12–17] When consumed alone on an empty stomach, tryptophan, a precursor of serotonin, is usually converted to serotonin. Hence, tryptophan can induce sleep and tranquility. This implies restoring serotonin levels lead to diminished depression precipitated by serotonin deficiencies.[8] Tyrosine and sometimes its precursor phenylalanine are converted into dopamine and norepinephrine.[18] Dietary supplements containing phenyl alanine and/or tyrosine cause alertness and arousal. Methionine combines with adenosine triphosphate (ATP) to produce S-adenosylmethionine (SAM), which facilitates the production of neurotransmitters in the brain.[19–22] The need of the present paradigm is, more studies shedding light on the daily supplemental doses of these neurochemicals that should be consumed to achieve antidepressant effects. Researchers attribute the decline in the consumption of omega-3 fatty acids from fish and other sources in most populations to an increasing trend in the incidence of major depression.[23] The two omega-3 fatty acids, eicosapentaenoic acid (EPA) which the body converts into docosahexanoic acid (DHA), found in fish oil, have been found to elicit antidepressant effects in human. Many of the proposed mechanisms of this conversion involve neurotransmitters. For instance, antidepressant effects may be due to bioconversion of EPA to leukotrienes, prostaglandins, and other chemicals required by the brain. Others hypothesize that both EPA and DHA influence neuronal signal transduction by activating peroxisomal proliferator-activated receptors (PPARs), inhibiting G-proteins and protein kinase C, in addition to calcium, sodium, and potassium ion channels. Whichever may be the case, epidemiological data and clinical studies have clearly shown that omega-3 fatty acids can effectively treat depression.[24] In depressed patients, daily consumption of dietary supplements of omega-3 fatty acid that contain 1.5-2 g of EPA has been shown to stimulate mood elevation. Nevertheless, doses of omega-3 higher than 3 g do not show better effects than placebos and may be contraindicative in cases, such as those taking anticlotting drugs.[25] In addition to omega–3 fatty acids, vitamin B (e.g., folate) and magnesium deficiencies have been linked to depression.[26–28] Randomized, controlled trials that involve folate and vitamin B12 suggest that patients treated with 0.8 mg of folic acid/day or 0.4 mg of vitamin B12/day will exhibit decreased depression symptoms.[27] In addition, the results of several case studies where patients were treated with 125-300 mg of magnesium (as glycinate or taurinate) with each meal and at bedtime led to rapid recovery from major depression in < 7 days for most of the patients. Previous research has revealed the link between nutritional deficiencies and some mental disorders.[232529–32] The most common nutritional deficiencies seen in patients with mental disorders are of omega–3 fatty acids, B vitamins, minerals, and amino acids that are precursors to neurotransmitters.[20232427283033] Accumulating evidence from demographic studies indicates a link between high fish consumption and low incidence of mental disorders; this lower incidence rate being the direct result of omega–3 fatty acid intake.[233132] One to two grams of omega-3 fatty acids taken daily is the generally accepted dose for healthy individuals, but for patients with mental disorders, up to 9.6 g has been shown to be safe and effective.[34–36] Majority of Asian diets are usually also lacking in fruits and vegetables, which further lead to mineral and vitamin deficiencies. The significance of various nutrients in mental health, with special relevance to depression has been discussed below. CARBOHYDRATES Carbohydrates are naturally occurring polysaccharides and play an important role in structure and function of an organism. In higher organisms (human), they have been found to affect mood and behavior. Eating a meal which is rich in carbohydrates triggers the release of insulin in the body. Insulin helps let blood sugar into cells where it can be used for energy and simultaneously it triggers the entry of tryptophan to brain. Tryptophan in the brain affects the neurotransmitters levels. Consumption of diets low in carbohydrate tends to precipitate depression, since the production of brain chemicals serotonin and tryptophan that promote the feeling of well being, is triggered by carbohydrate rich foods. It is suggested that low glycemic index (GI) foods such as some fruits and vegetables, whole grains, pasta, etc. are more likely to provide a moderate but lasting effect on brain chemistry, mood, and energy level than the high GI foods - primarily sweets - that tend to provide immediate but temporary relief. PROTEINS Proteins are made up of amino acids and are important building blocks of life. As many as 12 amino acids are manufactured in the body itself and remaining 8 (essential amino acids) have to be supplied through diet. A high quality protein diet contains all essential amino acids. Foods rich in high quality protein include meats, milk and other dairy products, and eggs. Plant proteins such as beans, peas, and grains may be low in one or two essential amino acids. Protein intake and in turn the individual amino acids can affect the brain functioning and mental health. Many of the neurotransmitters in the brain are made from amino acids. The neurotransmitter dopamine is made from the amino acid tyrosine and the neurotransmitter serotonin is made from the tryptophan.[5] If there is a lack of any of these two amino acids, there will not be enough synthesis of the respective neurotransmitters, which is associated with low mood and aggression in the patients. The excessive buildup of amino acids may also lead to brain damage and mental retardation. For example, excessive buildup of phenylalanine in the individuals with disease called phenylketonuria can cause brain damage and mental retardation. ESSENTIAL FATTY ACIDS Omega-3 fatty acids The brain is one of the organs with the highest level of lipids (fats). Brain lipids, composed of fatty acids, are structural constituents of membranes. It has been estimated that gray matter contains 50% fatty acids that are polyunsaturated in nature (about 33% belong to the omega-3 family), and hence are supplied through diet. In one of the first experimental demonstrations of the effect of dietary substances (nutrients) on the structure and function of the brain, the omega-3 fatty acids (specially alpha-linolenic acid, ALA) were the member to take part. An important trend has been observed from the findings of some recent studies that lowering plasma cholesterol by diet and medications increases depression. Among the significant factors involved are the quantity and ratio of omega-6 and omega-3 polyunsaturated fatty acids (PUFA) that affect serum lipids and alter the biochemical and biophysical properties of cell membranes. It has been hypothesized that sufficient long chain PUFAs, especially DHA, may decrease the development of depression.[37] The structural and functional components of membrane in cells of brain which is a lipid-rich organ, include polar phospholipids, spingolipids, and cholesterol. The glycerophospholipids in brain consist of high proportion of PUFA derived from the essential fatty acids (EFAs), linoleic acid and α-linolenic acid. The main PUFA in the brain are DHA, derived from the omega-3 fatty acid α-linolenic acid, arachidonic acid (AA) and docosa tetraenoic acid, both derived from omega-6 fatty acid linoleic acid. Experimental studies have revealed that diets lacking omega-3 PUFA lead to considerable disturbance in neural function.[38] Studies by Marszalek and Lodish indicate that despite their abundance in the nervous system, DHA and AA cannot be synthesized by mammals de novo and hence they or their precursors have to be supplied through the diet and transported to the brain. During late gestation and the early postnatal period, neurodevelopment occurs at significantly rapid rates which make the supply of adequate quantity of PUFAs, particularly DHA, imperative to ensure neurite outgrowth in addition to appropriate development of brain and retina.[39] Bruinsma and Taren of University of Arizona College of Public Health, Tucson, USA explored the involvement of dieting-related psychological factors as potential confounders.[40] They discussed studies that have both supported and contested the proposition that lowering plasma cholesterol by diet and medications contributes to depression. Research findings point out that an imbalance in the ratio of the EFAs, namely the omega-6 and omega-3 fatty acids, and/or a deficiency in omega-3 fatty acids, may be responsible for the heightened depressive symptoms associated with low plasma cholesterol. These relationships may explain the inconsistency in the results of trials on cholesterol-lowering interventions and depression. On similar lines, dieting behaviors have been associated with alterations in moods.[41] Dietary omega-3 fatty acids play a role in the prevention of some disorders including depression. Their deficiency can accelerate cerebral aging by preventing the renewal of membranes. However, the respective roles of the vascular component on one hand (where the omega-3s are active) and the cerebral parenchyma itself on the other, have not yet been clearly resolved. The role of omega–3 in certain diseases such as dyslexia and autism is suggested. It was omega–3 fatty acids that participated in the first coherent experimental demonstration of the effect of dietary substances (nutrients) on the structure and function of the brain. Experiments were first of all carried out on x-vivo cultured brain cells (1), then on in vivo brain cells (2), finally on physicochemical, biochemical, physiological, neurosensory, and behavioral parameters (3). These findings indicated that the nature of polyunsaturated fatty acids (in particular omega–3) present in formula milks for infants (both premature and term) determines the visual, cerebral, and intellectual abilities.[16] VITAMINS B-complex vitamins Nutrition and depression are intricately and undeniably linked, as suggested by the mounting evidence by researchers in neuropsychiatry. According to a study reported in Neuropsychobiology,[42] supplementation of nine vitamins, 10 times in excess of normal recommended dietary allowance (RDA) for 1 year improved mood in both men and women. The interesting part was that these changes in mood after a year occurred even though the blood status of nine vitamins reached a plateau after 3 months. This mood improvement was particularly associated with improved vitamin B2 and B6 status. In women, baseline vitamin B1 status was linked with poor mood and an improvement in the same after 3 months was associated with improved mood. Thiamine is known to modulate cognitive performance particularly in the geriatric population.[43] Vitamin B12 (Cynocobalamin) Clinical trials have indicated that Vitamin B12 delays the onset of signs of dementia (and blood abnormalities), if it is administered in a precise clinical timing window, before the onset of the first symptoms. Supplementation with cobalamin enhances cerebral and cognitive functions in the elderly; it frequently promotes the functioning of factors related to the frontal lobe, in addition to the language function of people with cognitive disorders. Adolescents who have a borderline level of vitamin B12 deficiency develop signs of cognitive changes.[43] Folate It has been observed that patients with depression have blood folate levels, which are, on an average, 25% lower than healthy controls.[44] Low levels of folate have also been identified as a strong predisposing factor of poor outcome with antidepressant therapy. A controlled study has been reported to have shown that 500 mcg of folic acid enhanced the effectiveness of antidepressant medication.[45] Folate's critical role in brain metabolic pathways has been well recognized by various researchers who have noted that depressive symptoms are the most common neuropsychiatric manifestation of folate deficiency.[46] It is not clear yet whether poor nutrition, as a symptom of depression, causes folate deficiency or primary folate deficiency produces depression and its symptoms. MINERALS Calcium A recent study showed that selective serotonin uptake inhibitors (SSRIs) inhibit absorption of calcium into bones. In addition to this, the SSRIs can also lower blood pressure in people, resulting in falls which may lead to broken bones. Indiscriminate prescription of SSRIs by doctors and ingestion by patients at risk of depression or other mental health problems may put them at increased risk of fractures. Compounded by the fact that they may be aging and already taking other medications, may also predispose them to osteoporosis.[47] Chromium Many studies on the association of chromium in humans depression have been recorded[4849] which indicate the significance of this micronutrient in mental health. Iodine Iodine plays an important role in mental health. The iodine provided by the thyroid hormone ensures the energy metabolism of the cerebral cells. During pregnancy, the dietary reduction of iodine induces severe cerebral dysfunction, eventually leading to cretinism. Iron Iron is necessary for oxygenation and to produce energy in the cerebral parenchyma (through cytochrome oxidase), and for the synthesis of neurotransmitters and myelin. Iron deficiency is found in children with attention-deficit/hyperactivity Iron in the are critical during the development of the and in with the in the with its associated deficiency is associated with disturbance in the development of cognitive Research findings out that as many as men are This in and more with of more depression than during other times in their These indicate the of in the of depression since its deficiency is known to cause and depression. Iron deficiency is for instance, with depression, and rapid a was first and by in while an of the mineral The role of has been well known in a into its its for bipolar disorder with and The therapeutic use of also its as an in depression, disorder, disorder, eating disorders, and in certain of adequate has to be taken while the mood in the can be used in patients with and The use of during and in and geriatric population needs observation about its In a of the of identified at studies, which indicate that low intake is associated with mood studies with with other populations that mood and in the of studies have shown that levels are lower in those with clinical intervention research that can influence the effectiveness of antidepressant also the brain cells the potential damage by studies have revealed the potential of the for physical development and mental development may be due to deficiency of When children and with poor nutritional status are to alterations of mental and behavioral they can be by dietary but to certain It has been observed that, of diet and meal pattern can have or immediate or effects. Dietary deficiencies of and nutrients vitamins, and such as during aging may precipitate brain which may be due to for of diet and depression which is a of to a factor that is often linked to increased and premature of aging may play an important role in this, by reducing food intake or reducing food intake in to such factors as in and poor use of prescription drugs, and and occurring in the in both and due to to They suggest changes associated with mental disorders such as dementia and depression, and and as to the of depression, people are the alternative and complementary are by the for and as a of and health and that are not currently to be a part of health need to be aware that it is likely that a of their patients with bipolar disorder might use these interventions to be and safe or to research in and brain indicates the of pathways that can provide a of the association between nutritional nervous system, and function an psychological health status. These findings may lead to of the therapeutic of dietary intervention health and health depression and other psychological disorders.

Indian Journal of Psychiatry · editorial or comment · 409 citationsread the source →

Intergenerational transmission of maltreatment and psychopathology: the role of antenatal depression.

Background: Maternal experience of childhood maltreatment and maternal antenatal depression are both associated with offspring childhood maltreatment and offspring adjustment problems. We have investigated the relative impact of maternal childhood maltreatment and exposure to depression in utero on offspring maltreatment and psychopathology. Method: The sample included 125 families from the South London Child Development Study. A prospective longitudinal design was used. Data on maternal childhood maltreatment, maternal antenatal depression (36 weeks of pregnancy), offspring childhood maltreatment (age 11 years) and offspring adolescent antisocial behaviour and depression (ages 11 and 16 years) were obtained from parents and offspring through clinical interview. Results: Mothers who experienced childhood maltreatment were significantly more likely to be depressed during pregnancy [odds ratio (OR) 10.00]. Offspring of mothers who experienced only childhood maltreatment or only antenatal depression were no more at risk of being maltreated or having psychopathology; however, offspring of mothers who experienced both maternal childhood maltreatment and antenatal depression were exposed to significantly greater levels of childhood maltreatment and exhibited significantly higher levels of adolescent antisocial behaviour compared with offspring not so exposed. Furthermore, maternal childhood maltreatment accounted for a significant proportion of the variance in offspring childhood maltreatment in only those offspring exposed to depression in utero. Conclusions: Maternal childhood maltreatment and maternal antenatal depression are highly associated. The co-occurrence of both insults significantly increases the risk of offspring adversity. The antenatal period is an optimum period to identify vulnerable women and to provide interventions.

Psychological medicine · 134 citationsread the source →

“Let Me See If I Have This Right …”: Words That Help Build Empathy

Medical Writings7 August 2001"Let Me See If I Have This Right …": Words That Help Build EmpathyJohn L. Coulehan, MD, Frederic W. Platt, MD, Barry Egener, MD, Richard Frankel, PhD, Chen-Tan Lin, MD, Beth Lown, MD, and William H. Salazar, MDJohn L. Coulehan, MDDr. Coulehan: State University of New York at Stony Brook; Stony Brook, NY 11794-8036Dr. Platt: University of Colorado Health Sciences Center; Denver, CO 80222Dr. Egener: American Academy on Physician and Patient; Portland, OR 97210Dr. Frankel: Highland Hospital; Rochester, NY 14620Dr. Lin: University of Colorado Health Sciences Center; Denver, CO 80222Dr. Lown: Mount Auburn Hospital; Cambridge, MA 02238Dr. Salazar: Medical College of Georgia; Augusta, GA 30902, Frederic W. Platt, MDDr. Coulehan: State University of New York at Stony Brook; Stony Brook, NY 11794-8036Dr. Platt: University of Colorado Health Sciences Center; Denver, CO 80222Dr. Egener: American Academy on Physician and Patient; Portland, OR 97210Dr. Frankel: Highland Hospital; Rochester, NY 14620Dr. Lin: University of Colorado Health Sciences Center; Denver, CO 80222Dr. Lown: Mount Auburn Hospital; Cambridge, MA 02238Dr. Salazar: Medical College of Georgia; Augusta, GA 30902, Barry Egener, MDDr. Coulehan: State University of New York at Stony Brook; Stony Brook, NY 11794-8036Dr. Platt: University of Colorado Health Sciences Center; Denver, CO 80222Dr. Egener: American Academy on Physician and Patient; Portland, OR 97210Dr. Frankel: Highland Hospital; Rochester, NY 14620Dr. Lin: University of Colorado Health Sciences Center; Denver, CO 80222Dr. Lown: Mount Auburn Hospital; Cambridge, MA 02238Dr. Salazar: Medical College of Georgia; Augusta, GA 30902, Richard Frankel, PhDDr. Coulehan: State University of New York at Stony Brook; Stony Brook, NY 11794-8036Dr. Platt: University of Colorado Health Sciences Center; Denver, CO 80222Dr. Egener: American Academy on Physician and Patient; Portland, OR 97210Dr. Frankel: Highland Hospital; Rochester, NY 14620Dr. Lin: University of Colorado Health Sciences Center; Denver, CO 80222Dr. Lown: Mount Auburn Hospital; Cambridge, MA 02238Dr. Salazar: Medical College of Georgia; Augusta, GA 30902, Chen-Tan Lin, MDDr. Coulehan: State University of New York at Stony Brook; Stony Brook, NY 11794-8036Dr. Platt: University of Colorado Health Sciences Center; Denver, CO 80222Dr. Egener: American Academy on Physician and Patient; Portland, OR 97210Dr. Frankel: Highland Hospital; Rochester, NY 14620Dr. Lin: University of Colorado Health Sciences Center; Denver, CO 80222Dr. Lown: Mount Auburn Hospital; Cambridge, MA 02238Dr. Salazar: Medical College of Georgia; Augusta, GA 30902, Beth Lown, MDDr. Coulehan: State University of New York at Stony Brook; Stony Brook, NY 11794-8036Dr. Platt: University of Colorado Health Sciences Center; Denver, CO 80222Dr. Egener: American Academy on Physician and Patient; Portland, OR 97210Dr. Frankel: Highland Hospital; Rochester, NY 14620Dr. Lin: University of Colorado Health Sciences Center; Denver, CO 80222Dr. Lown: Mount Auburn Hospital; Cambridge, MA 02238Dr. Salazar: Medical College of Georgia; Augusta, GA 30902, and William H. Salazar, MDDr. Coulehan: State University of New York at Stony Brook; Stony Brook, NY 11794-8036Dr. Platt: University of Colorado Health Sciences Center; Denver, CO 80222Dr. Egener: American Academy on Physician and Patient; Portland, OR 97210Dr. Frankel: Highland Hospital; Rochester, NY 14620Dr. Lin: University of Colorado Health Sciences Center; Denver, CO 80222Dr. Lown: Mount Auburn Hospital; Cambridge, MA 02238Dr. Salazar: Medical College of Georgia; Augusta, GA 30902Author, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-135-3-200108070-00022 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Consider these two physician–patient dialogues:1. Patient: You know, when you discover a lump in your breast, you kind of feel—well, kind of—(her speech tapers off; she looks down; tears form in her eyes).Dr. A: When did you actually discover the lump?Patient: (absently) I don't know. It's been a while.2. Patient: (same as above)Dr. B: That sounds frightening. Patient: Well, yeah, sort of. Dr. B: Sort of frightening?Patient: Yeah … and I guess I'm feeling like my life is over. Dr. B: I see. Worried and sad too. Patient: That's it, Doctor. Dr. A's patient ...References1. Konrad TR, Williams ES, Linzer M, McMurray J, Pathman DE, Gerrity M, et al . Measuring physician job satisfaction in a changing workplace and a challenging environment. SGIM Career Satisfaction Study Group. Society of General Internal Medicine. Med Care. 1999;37:1174-82. [PMID: 10549620] CrossrefMedlineGoogle Scholar2. Donelan K, Blendon RJ, Lundberg GD, Calkins DR, Newhouse JP, Leape LL, et al . The new medical marketplace: physicians' views. Health Aff Millwood. 1997;16:139-48. [PMID: 9314685] CrossrefMedlineGoogle Scholar3. Bates AS, Harris LE, Tierney WM, Wolinsky FD. Dimensions and correlates of physician work satisfaction in a midwestern city. Med Care. 1998;36:610-7. [PMID: 9544600] CrossrefMedlineGoogle Scholar4. McMurray JE, Williams E, Schwartz MD, Douglas J, Van Kirk J, Konrad TR, et al . Physician job satisfaction: developing a model using qualitative data. SGIM Career Satisfaction Study Group. J Gen Intern Med. 1997;12:711-4. [PMID: 9383141] CrossrefMedlineGoogle Scholar5. Beckman HB, Frankel RM. The effect of physician behavior on the collection of data. Ann Intern Med. 1984;101:692-6. [PMID: 6486600] LinkGoogle Scholar6. Marvel MK, Epstein RM, Flowers K, Beckman HB. Soliciting the patient's agenda: have we improved? JAMA. 1999;281:283-7. [PMID: 9918487] CrossrefMedlineGoogle Scholar7. Roter DL, Stewart M, Putnam SM, Lipkin M, Stiles W, Inui TS. Communication patterns of primary care physicians. JAMA. 1997;277:350-6. [PMID: 9002500] CrossrefMedlineGoogle Scholar8. White J, Levinson W, Roter D. "Oh, by the way …": the closing moments of the medical visit. J Gen Intern Med. 1994;9:24-8. [PMID: 8133347] CrossrefMedlineGoogle Scholar9. Nightingale SD, Yarnold PR, Greenberg MS. Sympathy, empathy, and physician resource utilization. J Gen Intern Med. 1991;6:420-3. [PMID: 1744756] CrossrefMedlineGoogle Scholar10. Levinson W, Stiles WB, Inui TS, Engle R. Physician frustration in communicating with patients. Med Care. 1993;31:285-95. [PMID: 8464246] CrossrefMedlineGoogle Scholar11. Levinson W, Gorawara-Bhat R, Lamb J. A study of patient clues and physician responses in primary care and surgical settings. JAMA. 2000;284:1021-7. [PMID: 10944650] CrossrefMedlineGoogle Scholar12. Suchman AL, Roter D, Green M, Lipkin M. Physician satisfaction with primary care office visits. Collaborative Study Group of the American Academy on Physician and Patient. Med Care. 1993;31:1083-92. [PMID: 8246638] CrossrefMedlineGoogle Scholar13. Cohen-Cole SA. The Medical Interview: The Three-Function Approach. St. Louis: Mosby; 1991. Google Scholar14. Coulehan JL, Block MR. The Medical Interview. Mastering Skills for Clinical Practice. 4th ed. Philadelphia: FA Davis; 2001. Google Scholar15. More ES. "Empathy" enters the profession of medicine.. In: More ES, Milligan MA, eds. The Empathic Practitioner. Empathy, Gender, and Medicine. New Brunswick, NJ: Rutgers Univ Pr; 1994:19-39. Google Scholar16. Basch MF. Empathic understanding: a review of the concept and some theoretical considerations. J Am Psychoanal Assoc. 1983;31:101-26. [PMID: 6681414] CrossrefMedlineGoogle Scholar17. Wispe L. History of the concept of empathy.. In: Eisenberg N, Strayer J, eds. Empathy and Its Development. Cambridge, UK: Cambridge Univ Pr; 1987:17-37. Google Scholar18. Book HE. Empathy: misconceptions and misuses in psychotherapy. Am J Psychiatry. 1988;145:420-4. [PMID: 3348445] CrossrefMedlineGoogle Scholar19. Buie DH. Empathy: its nature and limitations. J Am Psychoanal Assoc. 1981;29:281-307. [PMID: 7264177] CrossrefMedlineGoogle Scholar20. Wilmer HA. The doctor-patient relationship and the issues of pity, sympathy and empathy. Br J Med Psychol. 1968;41:243-8. [PMID: 5728595] CrossrefMedlineGoogle Scholar21. Strayer J. Affective and cognitive perspectives on empathy.. In: Eisenberg N, Strayer J, eds. Empathy and Its Development. Cambridge, UK: Cambridge Univ Pr; 1987:218-44. Google Scholar22. Brothers LA, Finch DM. Physiological evidence for an excitatory pathway from entorhinal cortex to amygdala in the rat. Brain Res. 1985;359:10-20. [PMID: 4075137] CrossrefMedlineGoogle Scholar23. Grattan LM, Eslinger PJ. Empirical study of empathy [Letter]. Am J Psychiatry. 1989;146:1521-2. [PMID: 2619825] CrossrefMedlineGoogle Scholar24. Katz RL. Empathy: Its Nature and Uses. New York: Free Press; 1963:26. Google Scholar25. Lief HI, Fox RC. Training for "detached concern" in medical students.. In: Lief HI, eds. The Psychological Basis of Medical Practice. New York: Harper & Row; 1963:12-35. Google Scholar26. Halpern J. Empathy: Using resonance emotions in the service of curiosity.. In: Spiro H, McCrea Curnen MG, Peschel E, St James D, eds. Empathy and the Practice of Medicine. New Haven, CT: Yale Univ Pr; 1993:160-73. Google Scholar27. Wispe L. The distinction between sympathy and empathy: to call forth a concept, a word is needed. Journal of Personality and Social Psychology. 1986;50:314-21. CrossrefGoogle Scholar28. Wilmer HA. The doctor-patient relationship and the issues of pity, sympathy and empathy. Br J Med Psychol. 1968;41:243-8. [PMID: 5728595] CrossrefMedlineGoogle Scholar29. Bertakis KD, Roter D, Putnam SM. The relationship of physician medical interview style to patient satisfaction. J Fam Pract. 1991;32:175-81. [PMID: 1990046] MedlineGoogle Scholar30. Roter D, Lipkin M, Korsgaard A. Sex differences in patients' and physicians' communication during primary care medical visits. Med Care. 1991;29:1083-93. [PMID: 1943269] CrossrefMedlineGoogle Scholar31. Levinson W, Roter D. Physicians' psychosocial beliefs correlate with their patient communication skills. J Gen Intern Med. 1995;10:375-9. [PMID: 7472685] CrossrefMedlineGoogle Scholar32. Spiro H. What is empathy and can it be taught? Ann Intern Med. 1992;116:843-6. [PMID: 1482433] LinkGoogle Scholar33. Brock CD, Salinsky JV. Empathy: an essential skill for understanding the physician–patient relationship in clinical practice. Fam Med. 1993;25:245-8. [PMID: 8319851] MedlineGoogle Scholar34. Platt FW, Keller VF. Empathic communication: a teachable and learnable skill. J Gen Intern Med. 1994;9:222-6. [PMID: 8014729] CrossrefMedlineGoogle Scholar35. Platt FW, Platt CM. Empathy: a miracle or nothing at all? Journal of Clinical Outcomes Management. 1998;5:30-3. Google Scholar36. Suchman AL, Markakis K, Beckman HB, Frankel R. A model of empathic communication in the medical interview. JAMA. 1997;277:678-82. [PMID: 9039890] CrossrefMedlineGoogle Scholar37. Charon R. The narrative road to empathy.. In: Spiro H, McCrea Curnen MG, Peschel E, St James D, eds. Empathy and the Practice of Medicine. New Haven, CT: Yale Univ Pr; 1993:147-59. Google Scholar38. Carson RA. Beyond respect to recognition and due regard.. In: Toombs SK, Barnard D, Carson RA, eds. Chronic Illness from Experience to Policy. Bloomington, IN: Indiana Univ Pr; 1995:105-28. Google Scholar39. Hunter KM, Charon R, Coulehan JL. The study of literature in medical education. Acad Med. 1995;70:787-94. [PMID: 7669155] MedlineGoogle Scholar40. Novack DH, Suchman AL, Clark W, Epstein RM, Najberg E, Kaplan C. Calibrating the physician. Personal awareness and effective patient care. Working Group on Promoting Physician Personal Awareness, American Academy on Physician and Patient. JAMA. 1997;278:502-9. [PMID: 9256226] CrossrefMedlineGoogle Scholar41. Coulehan JL. Tenderness and steadiness: emotions in medical practice. Lit Med. 1995;14:222-36. [PMID: 8558910] CrossrefMedlineGoogle Scholar42. Connelly J. Being in the present moment: developing the capacity for mindfulness in medicine. Acad Med. 1999;74:420-4. [PMID: 10219225] CrossrefMedlineGoogle Scholar43. Epstein RM. Mindful practice. JAMA. 1999;282:833-9. [PMID: 10478689] CrossrefMedlineGoogle Scholar44. Miller SZ, Schmidt HJ. The habit of humanism: a framework for making humanistic care a reflexive clinical skill. Acad Med. 1999;74:800-3. [PMID: 10429589] CrossrefMedlineGoogle Scholar45. Barrett-Lennard GT. The phases and focus of empathy. Br J Med Psychol. 1993;66 Pt 1 3-14. [PMID: 8485075] CrossrefMedlineGoogle Scholar46. Gallop R, Lancee WJ, Garfinkel PE. The empathic process and its mediators. A heuristic model. J Nerv Ment Dis. 1990;178:649-54. [PMID: 2230750] CrossrefMedlineGoogle Scholar47. Hall JA, Roter DL, Rand CS. Communication of affect between patient and physician. J Health Soc Behav. 1981;22:18-30. [PMID: 7240703] CrossrefMedlineGoogle Scholar48. Larsen KM, Smith CK. Assessment of nonverbal communication in the patient–physician interview. J Fam Pract. 1981;12:481-8. [PMID: 7462949] MedlineGoogle Scholar49. Suchman AL, Matthews DA. What makes the patient-doctor relationship therapeutic? Exploring the connexional dimension of medical care. Ann Intern Med. 1988;108:125-30. [PMID: 3276262] LinkGoogle Scholar50. Suchman AL. Control and Relation: Two Foundational Values and Their Consequences.. In: Suchman AL, Botelho RJ, Hinton-Walker P, eds. Partnerships in Healthcare: Transforming Relational Process. Rochester, NY: Univ of Rochester Pr; 1998. Google Scholar51. Branch WT, Malik TK. Using "windows of opportunities" in brief interviews to understand patients' concerns. JAMA. 1993;269:1667-8. [PMID: 8455300] CrossrefMedlineGoogle Scholar52. Pinderhughes EB. Teaching empathy: ethnicity, race and power at the cross-cultural treatment interface. American Journal of Social Psychology. 1984;4:5-12. Google Scholar53. Kleinman A, Eisenberg L, Good B. Culture, illness, and care: clinical lessons from anthropologic and cross-cultural research. Ann Intern Med. 1978;88:251-8. [PMID: 626456] LinkGoogle Scholar54. Platt FW, Gaspar DL, Coulehan JL, Fox L, Adler AJ, Weston WW, et al . "Tell me about yourself": the patient-centered interview. Ann Intern Med. 2001;134:1079-85. LinkGoogle Scholar Author, Article, and Disclosure InformationAffiliations: Dr. Coulehan: State University of New York at Stony Brook; Stony Brook, NY 11794-8036Dr. Platt: University of Colorado Health Sciences Center; Denver, CO 80222Dr. Egener: American Academy on Physician and Patient; Portland, OR 97210Dr. Frankel: Highland Hospital; Rochester, NY 14620Dr. Lin: University of Colorado Health Sciences Center; Denver, CO 80222Dr. Lown: Mount Auburn Hospital; Cambridge, MA 02238Dr. Salazar: Medical College of Georgia; Augusta, GA 30902Corresponding Author: John L. Coulehan, MD, Department of Preventive Medicine, HSC L3-086, State University of New York at Stony Brook, Stony Brook, NY 11794-8036; e-mail, [email protected]sunysb.edu. Current Author Addresses: Dr. Coulehan: Department of Preventive Medicine, HSC L3-086, State University of New York at Stony Brook, Stony Brook, NY 11794-8036.Drs. Platt and Lin: University of Colorado Health Sciences Center, 4200 East Ninth Avenue, Denver, CO 80222.Dr. Egener: American Academy on Physician and Patient, Legacy Clinic Northwest, 1130 NW 22nd Avenue, Suite 220, Portland, OR 97210.Dr. Frankel: Highland Hospital, 1000 South Avenue, Rochester, NY 14620.Dr. Lown: Mount Auburn Hospital, 300 Mt. Auburn Street, Cambridge, MA 02238.Dr. Salazar: Medical College of Georgia, 1120 15th Street, HS2010, Augusta, GA 30902. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited ByHow does narrative medicine impact medical trainees' learning of professionalism? A qualitative studyEmpathy in nurse-patient interaction: a conversation analysisPhysician empathy according to physicians: A multi-specialty qualitative analysisCompassion FatigueDefining clinical empathy: a grounded theory approach from the perspective of healthcare workers and patients in a multicultural settingEmpathy in patient care: from 'Clinical Empathy' to 'Empathic Concern'Introducing reflective narrative for first-year medical students to promote empathy as an integral part of physiology curriculumSoft Skills: The Case for Compassionate Approaches or How Behavior Analysis Keeps Finding Its HeartBedside Manner 2020: An Inventory of Best PracticesClinical Empathy for the Surgical Patient: Lessons From W.H. Auden's Prose and PoetryCraving Empathy: Studying the Sustained Impact of Empathy Training on CliniciansThe Development of Empathy and Associated Factors during Medical Education: A Longitudinal StudyComparison of self-reported empathy levels among dental undergraduate students in Northern India: A questionnaire-based cross-sectional studyThe role of compassion in ethical frameworks and medical practiceSearching for the erosion of empathy in medical undergraduate students: a longitudinal studyImproving Interactions with Healthcare Robots: A Review of Communication Behaviours in Social and Healthcare ContextsDevelopment and piloting of a Situational Judgement Test for emotion-handling skills using the Verona Coding Definitions of Emotional Sequences (VR-CoDES)The impact of therapeutic alliance in physical therapy for chronic musculoskeletal pain: A systematic review of the literatureFeelings Behind a Face: a Medical Student Counseling Workshop in Facial Reconstructive SurgeryAchieving positive outcomes in complex cases: The Admiral Nurse Dementia Helpline (Innovative Practice)Psychological phenomena in the doctor- Elderly patient relationshipApplying a critical race lens to relationship‐centered care in pregnancy and childbirth: An antidote to structural racismHow do perceptions of verbal statements and nonverbal actions as empathetic differ by medical appointment context?Practices to Foster Physician Presence and Connection With Patients in the Clinical EncounterRapport, Empathy and Professional Identity: Some Challenges for International Medical Graduates Speaking English as a Second or Foreign LanguageUnder what circumstances can immigrant patients and healthcare professionals co-produce health? - an interpretive scoping reviewClinical sympathy: the important role of affectivity in clinical practiceEmpathy in computer-mediated interactions: A conceptual framework for research and clinical practice. Psychotherapist's empathic responses to client's troubles telling/feelings talk in psychotherapy: A conversation analysisHow does medical education affect empathy and compassion in medical students? A meta-ethnography: BEME Guide No. 57Empathy in psychotherapy: Using conversation analysis to explore the therapists' empathic interaction with clientsThe Tinnitus Retraining Therapy Trial's Standard of Care Control Condition: Rationale and Description of a Patient-Centered ProtocolMultidisciplinary Teaming: Enhancing Collaboration through Increased UnderstandingCommunication in Health CareCommunication in Surgery for Patient SafetyAgents of empathy: How medical interpreters bridge sociocultural gaps in genomic sequencing disclosures with Spanish-speaking familiesThe development and psychometric validation of a Chinese empathy motivation scaleEmpathic and compassionate healthcare as a Christian spiritual practiceObesity bias among preclinical and clinical chiropractic students and faculty at an integrative health care institution: A cross-sectional studyEmpathy: From Attribute to RelationshipInfluences on students' empathy in medical education: an exploratory interview study with medical students in their third and last yearTeaching future doctors to communicate: a communication intervention for medical students in their clinical yearEmpathy in general practice: its meaning for patients and doctorsEmpathically designed responses as a gateway to advice in Dutch counseling callsAnnotating and modeling empathy in spoken conversationsEmpathy can make the difference. How?The Effect of Patient Participation through Physician's Resources on Experience and WellbeingDepression/AnxietySuffering, Hope, and HealingA Review of Empathy, Its Importance, and Its Teaching in Surgical TrainingAthletes' Perception of Athletic Trainer Empathy: How Important Is It?Empathy from the perspective of oncology nursesPatients' Trust in Physician, Patient Enablement, and Health-Related Quality of Life During Colon Cancer TreatmentMeasuring Medical Students' EmpathyEmpathy in the Clinician–Patient RelationshipComparing two types of perspective taking as strategies for detecting distress amongst parents of children with cancer: A randomised trialIf You Could Read My Mind: The Role of Healthcare Providers' Empathic and Communicative Competencies in Clients' Satisfaction with ConsultationsPatients who are anxious or fearfulFatigue: Has It Affected Your Compassion?Study on Empathy among Undergraduate Students of the Medical Profession in NepalPower Relations and Health Care Communication in Older Adulthood: Educating Recipients and ProvidersBreast Biopsies are Minimally Painful, Exceed Patient Expectations, and Do Not Represent a Genuine Lasting Harm for Most WomenSpirituality and Ubuntu as the foundation for building African institutions, organizations and leadersShowing you care: An empathetic approach to doctor–patient communicationEmpathy and affect: what can empathied bodies do?Computational Analysis and Simulation of Empathic Behaviors: a Survey of Empathy with in medical students and empathy is with differences in communication and in empathy: the to clinical and at the of Social of What it to of changing empathy and patient in healthcare to for and Chronic medical communication: the of by Care A and of the Therapy of undergraduate and students medical A longitudinal studyEmpathy: what does it for A qualitative empathic and compassionate patient care: education and to the Patient with and Student Empathy in Medical Students During a Clinical and patients' perspectives on empathy: of and treatment of Approaches to the of and of a Communication in for of Healthcare as a do primary care when patients during and of the of the in a general medicine Patient Satisfaction for the . . . of of Care in the development of doctor-patient a call and a care: Enhancing physician–patient communication and education in of to Hope, and of empathy in general practice: a systematic with of Cancer Patient: of an of empathy and correlates among types of in empathic in primary care for research and with an to patients in A new perspective on empathic A for about and in longitudinal study of in interaction in treatment of in empathy medical role of and in medical education: the as as the approach to an empathic understanding of among patients and in the of The of Role of Empathy in Therapy and the New Communication Skills Assessment by Patients and and EmpathyEmpathy and Its A Review of With Medical Students and the nature of in the for health and the does care of the of of a with by among and of A to for and to clinical empathic a of Empathy with Behavior Medical Communication in in for Communication to and Patient to and A of and Cancer the and of clinical empathy: A theoretical and a research of communication in the medical A review and Clinical Empathy: An about to Physician during Care MD, H. PhD, M. MD, and and role in education about care in Competencies in Care for and Communication in patients with in the Care of Cancer in of and of Empathic during When Being Not empathy learning for be and for effective the role of care in with and in the of the medicine and outcomes of physician empathy in A structural focus study of and perceptions of the of of Medical Student role of empathy in in the a new and in the a of the An or Do You to to Patients Do Not or with Challenges and a of of the of a for children with Care. A to in care: The role of perceptions in Older in Clinical during Health and H. or Not to Is That the Right empathy and sympathy: responses to troubles on a health care with to make the patient the Communication and With Patients in Your as a of The of Medicine, and How to and A Patient-Centered Communication Illness Using to Communication Care and Social in the office approach to the Words That in to and MD, M. MD, and Frederic Platt, I Student August August August by American College of

Annals of Internal Medicine · 322 citationsread the source →